Gliomas News and Research

RSS

Montreal researchers identifies two specific key players in growth of GBM

Glioblastoma (GBM) is the most common and deadly form of primary malignant brain cancer accounting for approximately 15% of all brain tumours and occurring mostly in adults between the ages of 45 and 70.

9 Jan 2014

Experimental drug that targets macrophages decreases cancer's growth

An experimental drug that targets macrophages, a type of immune cells, in the microenvironment surrounding the lethal brain tumor glioblastoma multiforme decreased the cancer's growth and extended survival of laboratory mice with the cancer, scientists will report on Tuesday Dec. 17, at the American Society for Cell Biology annual meeting in New Orleans.

16 Dec 2013

Researchers identify mechanism implicated in brain cancer and drug that decreases brain tumor growth

Researchers at the University of Calgary's Hotchkiss Brain Institute (HBI) have made a discovery that could lead to better treatment for patients suffering from brain cancer.

9 Dec 2013

Study finds two distinct subtypes in pediatric diffuse intrinsic pontine gliomas

Children's National researcher, Javad Nazarian, PhD, authored a new study entitled, "Comparative Multidimensional Molecular Analyses of Pediatric Diffuse Intrinsic Pontine Glioma Reveals Distinct Molecular Subtypes." The study found, for the first time, two distinct subtypes in pediatric diffuse intrinsic pontine gliomas.

4 Dec 2013

Study: Hospitals vary in management of children with traumatic brain injury

Hospitals vary in management of children with traumatic brain injury—particularly in monitoring and preventing the harmful effects of increased intracranial pressure (ICP), according to a study in the November issue of Neurosurgery, official journal of the Congress of Neurological Surgeons.

12 Nov 2013

Investigators find potential new target for treatment of low-grade gliomas

Investigators at Johns Hopkins have found a known genetic pathway to be active in many difficult-to-treat pediatric brain tumors called low-grade gliomas, potentially offering a new target for the treatment of these cancers.

7 Nov 2013

Angiochem presents results of Phase 2 study with ANG1005 in breast cancer patients with brain metastases

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), announced that the complete analysis results of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in breast cancer patients with brain metastasis were presented today at the 2013 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Conference.

23 Oct 2013

Angiochem initiates ANG1005 Phase 2 study in patients with recurrent high-grade glioma

Angiochem, a clinical stage biotechnology company developing drugs that are uniquely capable of crossing the blood-brain barrier (BBB), today announced the initiation of a Phase 2 clinical study with ANG1005, a novel paclitaxel-peptide drug conjugate, in patients with recurrent high-grade glioma.

22 Oct 2013

Researchers discover drug that halts growth of brain tumor cells

Working with mice, Johns Hopkins researchers have discovered that weeks of treatment with a repurposed FDA-approved drug halted the growth of - and ultimately left no detectable trace of - brain tumor cells taken from adult human patients.

24 Sep 2013

New cellular switch could eventually inhibit growth of aggressive malignant brain tumor

Researchers at UT Southwestern Medical Center have identified a cellular switch that potentially can be turned off and on to slow down, and eventually inhibit the growth of the most commonly diagnosed and aggressive malignant brain tumor.

21 Sep 2013

BMP linked to increased risk of benign tumors, not cancers

Patients undergoing spinal fusion surgery with bone morphogenetic protein (BMP) appear to be at increased risk of benign tumors—but not cancers, reports a study in the September issue of Neurosurgery, official journal of the Congress of Neurological Surgeons. The journal is published by Lippincott Williams & Wilkins, a part of Wolters Kluwer Health.

7 Sep 2013

ESMO recognises oncologists with prestigious awards

The European Society for Medical Oncology, the leading pan-European organisation representing medical oncology professionals, announced today the recipients of the annual society's prestigious awards, recognising excellence in oncology.

5 Sep 2013

Brain tumor cells in arrested development contribute to cell variety that protects cancer

A program that pushes immature cells to grow up and fulfill their destiny as useful, dedicated cells is short-circuited in the most common and deadly form of brain tumor, scientists at The University of Texas MD Anderson Cancer Center report this week in the Early Edition of the Proceedings of the National Academy of Sciences.

8 Aug 2013

Study reveals nearly 40% of tumors are caused by viruses

The results of a large-scale analysis of the association between DNA viruses and human malignancies suggest that many of the most common cancers are not associated with DNA viruses.

6 Aug 2013

3-D hydrogel approach to study aggressive and deadly forms of brain cancer

Human glioblastoma multiforme, one of the most common, aggressive and deadly forms of brain cancer, is notoriously difficult to study. Scientists have traditionally studied cancer cells in petri dishes, which have none of the properties of the brain tissues in which these cancers grow, or in expensive animal models.

24 Jul 2013

Combination therapy with myxoma virus and rapamycin can kill glioblastoma multiforme

A combination of the myxoma virus and the immune suppressant rapamycin can kill glioblastoma multiforme, the most common and deadliest malignant brain tumor, according to Moffitt Cancer Center research.

21 Jun 2013

Abnormal metabolic pathway drives cancer-cell growth in glioblastoma subtype

A study led by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified an abnormal metabolic pathway that drives cancer-cell growth in a particular glioblastoma subtype. The finding might lead to new therapies for a subset of patients with glioblastoma, the most common and lethal form of brain cancer.

14 Jun 2013

New weapon in the fight against childhood brain cancer emerges

A relatively new weapon in the fight against childhood brain cancer has emerged that improves upon standard magnetic resonance imaging by providing information about tumor metabolism and extent of cancer in children diagnosed with glioma, a growth caused by the abnormal division of glial cells in the brain, say researchers at the Society of Nuclear Medicine and Molecular Imaging's 2013 Annual Meeting.

11 Jun 2013

Scientists pinpoint genetic traits of cells that give rise to gliomas

A multi-institutional team of researchers have pinpointed the genetic traits of the cells that give rise to gliomas - the most common form of malignant brain cancer. The findings, which appear in the journal Cell Reports, provide scientists with rich new potential set of targets to treat the disease.

4 Jun 2013

Cytomegalovirus might accelerate the development of glioblastoma

A virus that infects most Americans but that usually remains dormant in the body might speed the progression of an aggressive form of brain cancer when particular genes are shut off in tumor cells, new research shows.

1 Jun 2013